PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation PRINCETON, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that two abstracts have been accepted for oral and poster presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22-26, 2025 in Boston, MA. Details for the presentations are as follows: Oral Presentation Title: Rezatapopt for locally advanced or metastatic solid tumors with a TP53 Y220C mutation: Initial analysis of the pivotal PYNNACLE Phase 2 trial Date and Time: Friday, October 24; 10:00 – 11:40 AM ET Session and Location: Clinical Trials Plenary Session; Level 3, Ballroom AB Presenter: Alison M. Schram, M.D., Memorial Sloan Kettering Cancer Center Poster Presentations Title: Rezatapopt for locally advanced or metastatic solid tumors with a TP53 Y220C mutation: Initial analysis of the pivotal PYNNACLE Phase 2 trial Date and Time: Friday, October 24; 12:30 – 4:00 PM ET Session and Location: Poster Session B; Exhibit Hall D Title: Natural history and prognostic value of TP53 Y220C mutation in advanced solid tumors: A real-world study Date and Time: Saturday, October 25; 12:30 – 4:00 PM ET Session and Location: Poster Session C; Exhibit Hall D About Rezatapopt Rezatapopt (PC14586) is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The U.S. Food and Drug Administration granted Fast Track designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation. About the PYNNACLE Clinical Trial The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. The primary objective of the Phase 1 portion of the clinical trial was to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D) of rezatapopt when administered orally to patients. Safety, tolerability, pharmacokinetics, and effects on biomarkers were also assessed. The Phase 2 portion is a registrational, single arm, expansion basket clinical trial comprising five cohorts (ovarian, lung, breast, and endometrial cancers, and other solid tumors) with the primary objective of evaluating the efficacy of rezatapopt at the RP2D in patients with TP53 Y220C and KRAS wild-type advanced solid tumors. For more information about the Phase 1/2 PYNNACLE clinical trial, refer to www.clinicaltrials.gov (NCT trial identifier NCT04585750). About PMV Pharma PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. The Company’s co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com . Contacts Investors Contact: Tim Smith Senior Vice President, Head of Corporate Development and Investor Relations [email protected] Media Contact: Kathy Vincent Greig Communications [email protected] Site - Investor Tools Print Email Alerts RSS Feeds Contact IR Email Page Overview Press Releases Events, Presentations & Publications Financials & Filings SEC Filings Quarterly Results Corporate Governance Governance Overview Committee Composition ESG Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Shareholder Services FAQ Email Alerts Contact IR About Management Board of Directors Scientific Advisory Boards Science p53 Overview p53 and Cancer Drug Discovery Pipeline PMV Pipeline PC14586 Clinical Trials Access to Investigational Product Investors Overview Press Releases Events, Presentations & Publications Financial & Filings Corporate Governance ESG Stock Information Shareholder Services Life at PMV Working at PMV Job Opportunities Contact Site - Mobile Home About Management Board of Directors Scientific Advisory Board Science p53 Overview p53 and Cancer Drug Discovery Pipeline PMV Pipeline PC14586 Investors Overview Press Releases Events & Presentations Financial & Filings SEC Filings Quarterly Results Corporate Governance Governance Overview Committee Composition Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Shareholder Services FAQ Email Alerts Contact IR Life at PMV Working at PMV Job Opportunities Contact Terms of Use Privacy Policy © 2026 PMV Pharmaceuticals, Inc. All rights reserved Terms of Use Privacy Policy var s_CCSWebHostingAccount = "trcgpmvpharma"; {"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/8916","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb54281\/themes\/site\/nir_pid3708"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNkdFOQyEMhl9oOSzxQt-mKVA3PNCetJ26tx8Dk21Go-ECWj769y9cFJCxnr0kC3wfLZglElQ8cTru-E9wU8kDi2g0iJKE7THlIjWijmRaKRcXhYzeV6xk4XZcXlXYiWfNhrqSDxJilbSGIW8Oil740BV6wSOq_ws3GCK_sI2QQSlJa12_PxC-r32qXlpvHcNjOG43PEyn18OCb_gJmDOkimaAldTtBy4Nqw525tStMNMc0Vby0_P-Jcg7qZY8G_6gaMUJWPr0aX7Gt9zyte-se6YWrvO_ACjLwj8","theme":"nir_pid3708","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"776a5e6e926dfdaeca537c841bd13516453586e98bf383c19fc986c368e43298"}}

The release as fetched from its publisher. pmvpharma.com ↗